Quest Diagnostics Incorporated (DGX)
| Market Cap | 15.50B |
| Revenue (ttm) | 9.30B |
| Net Income (ttm) | 763.00M |
| Shares Out | 112.44M |
| EPS (ttm) | 6.71 |
| PE Ratio | 20.55 |
| Forward PE | 15.42 |
| Dividend | $2.84 (2.06%) |
| Ex-Dividend Date | Jan 16, 2024 |
| Volume | 402,619 |
| Open | 137.34 |
| Previous Close | 137.66 |
| Day's Range | 137.03 - 138.00 |
| 52-Week Range | 119.59 - 157.36 |
| Beta | 0.90 |
| Analysts | Hold |
| Price Target | 149.17 (+8.19%) |
| Earnings Date | Feb 1, 2024 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent ... [Read more]
Financial Performance
In 2022, DGX's revenue was $9.88 billion, a decrease of -8.39% compared to the previous year's $10.79 billion. Earnings were $946.00 million, a decrease of -52.58%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for DGX stock is "Hold." The 12-month stock price forecast is $149.17, which is an increase of 8.19% from the latest price.
News
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J. , Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and...
Quest Diagnostics Names Yuri A. Fesko, M.D.
Seasoned healthcare executive and oncologist joins Executive Leadership Team SECAUCUS, N.J. , Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic i...
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J. , Dec. 19, 2023 /PRNewswire/ -- Quest Diagnostics...
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
BALTIMORE , Dec. 14, 2023 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncol...
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J. , Dec. 7, 2...
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year
SECAUCUS, N.J. , Dec. 6, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has ...
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, N.J. and WALTHAM, Mass.
Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics Financing to support UDX's pursuit of FDA premarket approval f...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Nov. 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a qu...
Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States
Quest Mobile™ has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023 SECAUCUS, N.J. , Nov. 9, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's l...
Quest Diagnostics Prices $750 Million of Senior Notes
SECAUCUS, N.J. , Oct. 30, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offe...
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology
—Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict® in the United States, Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests— —Validating Cl...
Quest Diagnostics profit falls 12%, but beats estimate
Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted thir...
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9% from ...
Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing
Relationship features use of Quest's distributed network of labs to deliver fast testing times in local communities around the United States LITTLETON, Colo. , Oct. 5, 2023 /PRNewswire/ -- Neway, LLC,...
Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023
SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2...
Quest Diagnostics to Speak at the Baird 2023 Global Healthcare Conference
SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice Pre...
Quest Diagnostics Releases 2022 Corporate Responsibility Report
SECAUCUS, N.J. , Sept. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report.
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, Mass.
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest Diagnost...
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer's disease
Quest Diagnostics Inc. DGX, +0.10% said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer's disease to market and it's now available for consumer pu...
Quest Diagnostics launches Alzheimer's blood test for consumers
Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.
Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
AD-Detect™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to help ...
Quest Diagnostics beats profit estimates as routine testing picks up
Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pand...
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5% from ...